Drug intelligence / Profile preview

sarperin

Development stage: Preclinical
Lead developer: Sinopharm Luya Pharmaceutical
Administration: Intramuscular, Subcutaneous, Intratumoral, Intracavitary

Overview

Sarperin, also known as 沙培林 or Streptococcus A Group For Injection, is a biological product derived from penicillin-treated Group A hemolytic Streptococcus. It is utilized as an auxiliary treatment for malignant tumors, including malignant pleural effusion, often in conjunction with surgery, radiotherapy, or chemotherapy. It is administered via intramuscular, subcutaneous, intratumoral, or intracavitary injection.

Brand names: 沙培林
Other names: salpeilin注射用A群链球菌Streptococcus A Group For InjectionZhusheyong A Qun Lianqiujun

Beyond the preview

Go deeper on sarperin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sarperin.

Explore the full profile